Inflammatory Bowel Disease (IBD) is a highly debilitating and potentially fatal idiopathic disorder of the intestinal tract which is exceedingly prevalent in westernized society; however there is concern of an IBD epidemic in Asia due to increasing incidence rates. There is no cure for IBD with current treatments limited by their inefficacy, toxicity and adverse side-effects; thus necessitating the search for novel therapies. In the past decade mesenchymal stem cells (MSCs) have become attractive candidates for the cellular based therapy of IBD. MSCs are easily isolated and expanded from adult bone-marrow and adipose tissue; they possess unique therapeutic characteristics including the ability to home to sites of tissue damage and inflammation, facilitate tissue repair and modulate the immune system. The administration of MSCs in animal models of experimental colitis and clinical trials of fistulising and luminal Crohn's disease have yielded promising results, however an unequivocal therapeutic mechanism remains elusive. This review will explore the clinical application of MSCs in IBD and current evidence from experimental models of colitis elucidating their potential to ameliorate intestinal inflammation.
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All phenotypes of IBD greatly affect quality of life with symptoms including ulcerations, fistulae, strictures, perianal fissures, bloody stool, persistent diarrhea or constipation, abdominal pain and cramps 2) . Potential complications in IBD such as perforation, excessive bleeding from ulcerations, obstruction of the bowel and intestinal scarring resulting in malnutrition can lead to fatality. Furthermore, the risk of developing cancers including colorectal cancer 3) and lymphoma 4) are increased in IBD resulting in an indirect escalation in the mortality rate. Although IBD is predominantly a disease of westernized society, dramatic increases in the incidence of IBD have been observed throughout Asia 5) which may reach epidemic proportions 6) .
The cause of IBD is unknown but concordant twin studies have revealed that the development of IBD is likely to require a multi-genetic predisposition and an environmental perturbation 7) . Numerous predisposing genes for CD and UC have been uncovered with around 30% of loci overlapping for both diseases suggesting similarities in pathological mechanisms 8) . Although the pathogenesis of IBD is unknown, it is predicted that antigens of commensal bacteria in the gut instigate an exaggerated immune response 9) . The role of epithelial permeability and leukocyte dysregulation in the exuberant antigen response is currently under investigation 10, 11) .
Current treatment strategies do not provide a cure and are limited by their inefficacy, toxicity and adverse sideeffects [12] [13] [14] ; thus necessitating the search for novel therapies. One of the most promising treatments currently being investigated is mesenchymal stem cell (MSC) therapy.
MSCs are easily isolated and expansively cultured from adult adipose tissue and bone marrow 15) . Furthermore, MSCs possess many unique properties making them an ideal candidate therapy for IBD. MSCs are immune evasive and can be transplanted between individuals and across species 16, 17) . Once administered, MSCs migrate through chemotaxis towards sites of inflammation; thus specifically targeting pathological manifestations 18) . After homing to the site of inflammation, MSCs facilitate tissue regeneration through secretion of pro-angiogenic and trophic factors which have been shown to promote endogenous repair mechanisms [19] [20] [21] . Moreover, MSCs are immunomodulatory and secrete anti-inflammatory factors suppressing the immune response and inflammation 22) . The clinical application of MSCs in CD and evidence for the possible mechanisms elucidating their potential to regenerate intestinal epithelium and reduce inflammation in experimental models of colitis will be reviewed.
Efficacy of MSCs in Clinical Trials
Clinical trials using MSCs for the treatment of CD fistulae and luminal inflammation have demonstrated that MSC therapy in IBD is both efficacious and feasible (summarised in and complex perianal fistulae in the majority of subjects.
Fibrin glue was regularly used in conjunction with local MSC administration in fistulising CD, however evidence of a therapeutic benefit is not likely to be a result of fibrin glue alone 23, 24) . One clinical trial demonstrated that in vitro expansion is likely to be essential in harnessing the therapeutic potential of AT-MSCs rather than treating patients with the primary stromal vascular fraction of lipoaspirate 25) .
The therapeutic outcome of MSC therapy in fistulising CD may be dose-dependent with greater efficacy achieved by doses of 2x10 7 or 4x10 7 MSCs/ml compared to 1x10 7 MSCs/ml 26) . Long-term effects have been reported with CD and perianal activity index scores declining 12 months post treatment 27) . Furthermore, sustained closure of fistulae has been achieved in 88-100% of subjects 8-12 months after a course of MSC therapy 26, 28) ; however these effects are relatively transient given that only 58% of subjects maintain closure after 3 years 29) . This suggests that repeated treatment may be required to maintain the therapeutic benefits of MSC therapy.
While autologous and allogeneic AT-MSCs have both demonstrated efficacy in the healing of fistulae, further evidence is required to determine long-term immune tolerance in patients with repeated allogeneic MSC exposure.
Bacterial contamination has posed a problem in the expansion of autologous MSCs in the past causing delay in treatment 24, 30) . If allogeneic MSCs are determined to be equally efficacious, pre-prepared sources for treatment could prevent such setbacks.
One clinical trial has determined that MSCs were as effective in treating fistulae of cryptoglandular origin as they were for fistulae resultant of CD 23) . 30) .
The cellular phenotype of MSCs post administration is poorly understood, however, differentiation into extraneous cell types has been rarely reported. Evidence from an in vitro study demonstrates that MSC differentiation into a myofibroblastic-like phenotype is subsequently reversible rather than committing, therefore MSCs are likely to possess a dynamic phenotype which is dependent on the in vivo signalling milieu 31) .
A clinical trial demonstrating the immunosuppressive effect of autologous bone marrow-derived MSCs (BMMSCs) has been successful in the treatment of fistulising have been assessed in two clinical trials 32, 33) . In a study Endoscopy revealed a reduction in mucosal inflammation in only 2/9 subjects, however biopsies of the inflamed mucosa revealed a decrease in CD4 + T-cells. This suggests that
MSCs suppressed the adaptive immune response; however subjects in this study suffered from refractory CD and were unresponsive to conventional treatment which may explain the poor results of the trial. Recently, Forbes et al. 33) successfully achieved clinical remission and endoscopic improvement in Crohn's colitis and ileocolitis in over half of subjects intravenously administered with allogeneic BMMSCs. These favourable results indicate that MSCs could be a viable therapeutic option for intestinal inflammation;
however experimental models are required to explore the mechanisms underlying therapeutic efficacy and safety of MSC therapy.
Route of MSC administration
MSCs have been predominantly administered by local injection directly into the fistulae or surrounding tissues in clinical trials (Table 1) . Despite the success of this method in fistulising CD, alternative administration routes that facilitate homing to multiple inflammatory sites may be required to treat pathological manifestations of IBD in its entirety. Systemic administration of MSCs was used in clinical trials treating luminal CD 32, 33) and is predominant in studies of experimental colitis ( 34, 35) however other studies have not observed this phenomenon [36] [37] [38] . Additionally, it is likely that MSCs can become sequestered in other various tissues connected to the circulatory system when systemically injected 39) . The high first pass effect and difficulty of homing may account for large quantities of MSCs used in clinical trials. Administering the supernatant of MSCs, also termed "conditioned media", via enema could be a feasible solution to effectively target the site of inflammation and eliminate the use of live cells 40) . Although, this method could potentially be safer and more efficacious, the invasiveness of the procedure and distance of pathological manifestations from the rectum in some cases of IBD could pose limitations.
Safety considerations
Despite favourable results of limited clinical trials there is no consensus regarding the long-term safety of MSC therapy. Some adverse events and hospitalizations were reported, however, these were thought to be unrelated to MSC therapy. An allergic reaction after treatment was reported however this was suggested to be a result of dimethyl sulfoxide used for cryopreservation 32) . Dysplastic lesions were discovered in a subject during endoscopy 42 days post initial MSC treatment 33) . The subject was subsequently diagnosed with sigmoidal adenocarcinoma.
A sigmoid mucosal biopsy revealed low-grade dysplasia upon entry into the study therefore it is unlikely that MSCs transformed into the dysplastic tissue in this case. The contribution of MSCs to the development of cancer is contentious and warrants further investigation. The limited self renewal capacity of MSCs combined with data from clinical trials and experimental models predicate a low probability of tumour formation and malignancy 41) . However,
MSCs have been implicated in the progression of cancer by enhancing tumour growth and metastasis [42] [43] [44] . Furthermore, sarcoma development has been observed after MSC administration in mice 45) with other studies reporting spontaneous transformation of MSCs in vitro after long-term culturing 46, 47) . Therefore, screening before administration of MSCs and in vitro quality control need to be considered in the future as preventive measures.
Proposed Therapeutic Mechanism of Mesenchymal Stem Cells in Colitis
While clinical trials have demonstrated the efficacy and safety of MSC therapy in fistulising CD, the mechanisms of the therapeutic effects of MSCs in IBD are less understood.
Animal models are relied upon to assess the feasibility of MSC treatment in colitis and provide an insight into potential mechanisms of action underlying the successful attenuation of colitis (summarised in Table 2 ).
Epithelial Integrity
The intestinal epithelium creates a distinct barrier protecting underlying tissues from pathogens in the gut lumen.
Restoration of epithelial integrity has been predicted to ameliorate the excessive immune response in IBD by preventing interaction with foreign antigens 10, 48) . Table 2 Mesenchymal stem cell treatment in experimental colitis models attenuation of gross morphological damage through MSC treatment is regularly demonstrated in experimental colitis.
Macroscopically, MSCs home to inflamed tissues, reduce ulceration and prevent fibrosis 34, 49, 50) . Histopathologically, MSCs prevent the loss and discontinuity of the surface columnar epithelial lining and derangement of the crypts 51) .
A protective effect on intestinal mucin secreting cells has also been observed 51, 52) . It has been suggested that MSCs have a regenerative effect by promoting the proliferation of intestinal epithelial cells and the differentiation of intestinal stem cells 49, 53) . Moreover, it has been reported that MSCs stimulate endogenous mechanisms of intestinal epithelial repair 21) . MSC-conditioned medium decreases epithelial damage in colitis highlighting the significance of the MSC secretome 40) . Regeneration of intestinal epithelium has been attributed to the secretion of angiogenic and trophic factors including vascular endothelial growth factor (VEGF), hepatocyte growth factor (HGF) and adiponectin detected in vitro MSC culture 40, 49) . Reduction in the levels of VEGF and HGF has been reported in the inflamed colon after MSC administration 36) , however MSCs have been observed to localize to the basal crypts 36) and express VEGF and , which may prevent inflammation-induced increase in epithelial permeability; and thus avert antigenic insult (Fig.   1 ).
Immunomodulation
The immunomodulatory properties of MSCs in models of experimental colitis have been well documented. MSCs reduce in vivo levels of pro-inflammatory cytokines and increase the production of anti-inflammatory cytokines in the gut and serum (Table 3 ). Conditioned medium has been shown to ameliorate the effects of colitis suggesting that the therapeutic value of MSCs is harnessed from secreted factors present in the secretome. TGF-β1 secreted by
MSCs in vitro 55) is elevated in the intestinal homogenate after in vivo MSC administration 53) ; inhibition of TGF-β1
signalling abrogates the therapeutic effect of MSC in experimental colitis 56) . Therefore TGF-β1 may be a common link between the therapeutic effect of conditioned medium and administered MSCs in vivo . Additionally, interleukin (IL)-10, which is theorized to be a target in the amelioration of enterocolitis 57) , was elevated in the intestine and serum after MSC treatment of experimental colitis 37, 53, 58) . However, there is no evidence of IL-10 secretion by unstimulated MSCs in culture 59, 60) . It has been established that MSCs can be potentiated by tumour necrosis factor (TNF)-α,
interferon (IFN)-γ and toll-like receptor (TLR) activation
to induce an anti-inflammatory phenotype 61, 62) ; therefore the possibility that the inflammatory microenvironment or the gut flora could upregulate anti-inflammatory factors including IL-10, indoleamine 2,3-dioxygenase (IDO) and prostaglandin E2 (PGE2) cannot be disregarded.
MSCs instigate leukocytes to mediate their immunomodulatory effects in gastrointestinal inflammation (Fig.   2 ). The innate immune system is critical in IBD pathology and mass neutrophil infiltration is utilized in CD diagnosis.
In experimental colitis, MSCs prevent neutrophil invasion and thus damage from cytotoxic granules 35, 49, 63) Bain et al . 64) suggested that resident macrophages in ↑ -increase, ↓ -decrease, N.D.-no difference, AT -adipose tissue, BM -bone marrow, UC -umbilical cord, IL -interleukin, TGF-β1 -transforming growth factor β1, TNF-α -tumour necrosis factor-α, CCL5 -chemokine ligand 5, MIP-2 -macrophage inflammatory protein-2, IFN-γ -interferon-γ, bFGF -basic fibroblast growth factor, VEGF -vascular endothelial growth factor, HGF -hepatocyte growth factor. Table 3 . When administered into an experimental colitis model Mφ2 successfully attenuated the clinical and histopathological severity of colitis 65) . . Increased Tregs are observed after the amelioration of experimental colitis via MSC treatment 53, 58) .
Additionally, mucosal and peripheral Tregs are elevated after MSC therapy in human fistulising CD 27) . Implantation of T-cells after MSC conditioning ameliorates experimental colitis 37, 63) . This suggests that the anti-inflammatory effect of MSCs in colitis is mediated, at least in part, by Tregs.
Recent evidence has suggested that an additional T-cell subset, mucosa-associated invariant T (MAIT) cells, may be implicated in the pathophysiology of experimental colitis and IBD 66, 67) ; however the influence of MSCs on MAIT
phenotypes is yet to be explored. for neutrophil recruitment 74) , therefore Treg suppression of Th17 may coincide with decreased neutrophil invasion observed after MSC treatment of experimental colitis 35) .
Additionally, Tregs have been demonstrated to promote anti-inflammatory properties in neutrophils 75) . Thus, Tregs may further suppress the inflammatory response by directly acting on the innate immune system.
Future Outlook
Currently 
